Skip to main content

Table 4 Histometric, neuropathology, clinical and BIE correlates

From: Post-mortem histopathology underlying β-amyloid PET imaging following flutemetamol F 18 injection

mCERADSOT Amyloid phase % Amyloid IHC Dx AD (NIA-RI) Dx AD (NIA-AA) Braak stage Cortical atrophy SUVR Dementia BIE positivity   
(Quantitative) (Ordinal) (Quantitative) (Ordinal) (Ordinal) (Ordinal) (Ordinal) (Quantitative) (Nominal) (Nominal)   
P < 0.0001 P < 0.0001 P = 0.0005 P < 0.0001 P < 0.0001 P < 0.0001 P = 0.2518 P < 0.0001 P = 0.0009 P < 0.0001 CERAD (Ordinal)
  P < 0.0001 P = 0.0014 P < 0.0001 P < 0.0001 P < 0.0001 P = 0.3569 P < 0.0001 P = 0.0021 P < 0.0001 mCERADSOT (Quantitative)
   P < 0.0001 P < 0.0001 P < 0.0001 P < 0.0001 P = 0.6275 P < 0.0001 P < 0.0001 P < 0.0001 Amyloid Phase (Ordinal)
    P = 0.0001 P < 0.0001 P = 0.0001 P = 0.9266 P < 0.0001 P = 0.8746 P < 0.0001 % amyloid IHC (Quantitative)
     P < 0.0001 P < 0.0001 P = 0.2087 P < 0.0001 P < 0.0001 P < 0.0001 AD (NIA-RI) (Ordinal)
      P < 0.0001 P = 0.2758 P < 0.0001 P < 0.0001 P < 0.0001 AD (NIA-AA) (Ordinal)
       P = 0.4195 P < 0.0001 P < 0.0001 P < 0.0001 Braak Stage (Ordinal)
        P = 0.1778 P = 0.4006 P = 0.7397 Cortical atrophy (Ordinal)
         P = 0.0041 P < 0.0001 SUVR (Quantitative)
          P < 0.0001 Dementia (Nominal)
  1. mCERAD SOT modified CERAD Standard of Truth, IHC Immunohistochemistry, Dx AD (NIA-RI) Neuropathological diagnosis of AD likelihood using the National Institute of Ageing – Reagan Institute criteria [9], Dx AD (NIA-AA) Neuropathological diagnosis of AD likelihood using the National Institute of Ageing – Alzheimer’s Association criteria [8], SUVR Standard retention value ratio normalised to the cerebellar cortex, BIE Blinded Image evaluation of PET images, CERAD Consortium to Establish a Registry for Alzheimer’s Disease
  2. Statistical tests were performed as indicated in the insert panel. mCERADSOT, % area amyloid IHC and SUVR values are continuous variables. All other variables are either categorical; CERAD (None, Sparse, Moderate, Frequent); Amyloid Phase (phases 0, 1, 2, 3, 4 and 5); Dx AD (NIA-RI) (Normal, Low, Intermediate or High - likelihood of AD), Dx AD (NIA-RI) (Not, Low, Intermediate or High – level of AD neuropathologic change), Braak Stage (Stage 0, I, II, III, IV, V and VI); Cortical atrophy (None, Mild, Moderate, Severe), or nominal; Dementia (Yes or No); BIE positivity (Normal Abnormal). All tests were performed using Spearman except BIE positivity vs Dementia which was perfomed using Chi-square test. Plots for some BIE positivity correlations are presented in Figs. 2 and 4